Margaret Sheridan-Pereira1, Joan Murphy, Julie Sloan, Gloria Crispino, Anne Leahy, J David Corcoran, Eugene Dempsey, Basil Elnazir, Patrick Gavin, Farhana Sharif, Rizwan Gul, Salius Satas, John Murphy, Siobhan Gormally, Issam Shanaa, David Waldron, Paul Mc Mahon, John Carson, Maarten Blanken, Louis Bont, Bosco Paes. 1. From the *Department of Paediatrics and Newborn Medicine, Coombe Women and Infants University Hospital, Dublin; †Department of Paediatrics, Trinity College Dublin, Dublin; ‡National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Crumlin, Dublin; §Department of Pediatrics, Cavan General Hospital, Cavan, Dublin; ¶Children's University Hospital, Dublin; ‖Department of Paediatrics, Cork University Maternity Hospital, Wilton, Cork; **Department of Paediatrics, AMNCH Tallaght Hospital, Dublin; ††Department of Paediatrics, Rotunda Hospital, Dublin; ‡‡Department of Pediatrics, Midlands Regional Hospital, Mullingar; §§Department of Pediatrics, Midlands Regional Hospital, Portlaoise; ¶¶Department of Pediatrics, Mt. Carmel Hospital, Dublin; ‖‖Department of Pediatrics, National Maternity Hospital, Dublin; ***Department of Pediatrics, Our Lady of Lourdes Hospital, Drogheda, Co Louth; †††Department of Pediatrics, South Tipperary General Hospital, Clonmel; ‡‡‡Department of Pediatrics, St. Luke's Hospital, Kilkenny; §§§Department of Pediatrics, Waterford Regional Hospital, Waterford; ¶¶¶Department of Pediatrics, Wexford General Hospital, Wexford, Ireland; ‖‖‖Division of Pediatric Immunology and Infectious Diseases, Wilhelmina Children's Hospital, University Medical Centre Utrecht, The Netherlands; and ****Department of Paediatrics, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: In several countries, respiratory syncytial virus prophylaxis is offered to late preterm infants who are at escalated risk of respiratory syncytial virus hospitalization (RSVH). However, targeted prophylaxis should be informed by country-specific data. This study, which uniquely includes 36 weeks of gestational age (GA) infants, aims to establish the risk factors for RSVH in 32-36 weeks of GA infants in Ireland. METHODS: A prospective observational study at 13 hospitals of laboratory-confirmed RSVH in nonprophylaxed 32-36 weeks of GA infants was conducted from July 2011 to February 2014. Baseline and first-year clinical data were analyzed by using SPSS software Version 22 (IBM Corp, Armonk, NY). Significant (P < 0.05) variables were entered into multiple logistic regression to determine the independent risk factors for RSVH. RESULTS: Sixty-three percent of eligible infants (1825 of 2877) were recruited. The RSVH rate was 3.6% (65 of 1807 analyzed infant records). There was no RSV-attributable mortality. Twelve infants required intensive care. Of the 15 variables correlating to RSVH, 5 independent risk factors were identified: older siblings [odds ratio (OR): 3.8; 95% confidence interval (CI): 1.97-7.41], being Caucasian (OR: 2.3; 95% CI: 1.04-5.29), neonatal respiratory morbidity (OR: 2.2; 95% CI: 1.28-3.94); birth July 15 to December 15 (OR: 2.1; 95% CI: 1.09-3.92) and family history of asthma (OR: 1.9; 95% CI: 1.01-3.39). Birth from 36 weeks to 36 + 6 days mitigated RSVH risk (relative risk: 0.58; 95% CI: 0.34-0.99); however, risk factors were similar to the 32-35 weeks of GA cohort. CONCLUSION: Neonatal respiratory morbidity or being Caucasian were the population-specific independent risk factors for RSVH in 32-36 weeks of GA in Ireland, whereas the other identified independent risk factors mirrored those established in previous studies.
BACKGROUND: In several countries, respiratory syncytial virus prophylaxis is offered to late preterm infants who are at escalated risk of respiratory syncytial virus hospitalization (RSVH). However, targeted prophylaxis should be informed by country-specific data. This study, which uniquely includes 36 weeks of gestational age (GA) infants, aims to establish the risk factors for RSVH in 32-36 weeks of GA infants in Ireland. METHODS: A prospective observational study at 13 hospitals of laboratory-confirmed RSVH in nonprophylaxed 32-36 weeks of GA infants was conducted from July 2011 to February 2014. Baseline and first-year clinical data were analyzed by using SPSS software Version 22 (IBM Corp, Armonk, NY). Significant (P < 0.05) variables were entered into multiple logistic regression to determine the independent risk factors for RSVH. RESULTS: Sixty-three percent of eligible infants (1825 of 2877) were recruited. The RSVH rate was 3.6% (65 of 1807 analyzed infant records). There was no RSV-attributable mortality. Twelve infants required intensive care. Of the 15 variables correlating to RSVH, 5 independent risk factors were identified: older siblings [odds ratio (OR): 3.8; 95% confidence interval (CI): 1.97-7.41], being Caucasian (OR: 2.3; 95% CI: 1.04-5.29), neonatal respiratory morbidity (OR: 2.2; 95% CI: 1.28-3.94); birth July 15 to December 15 (OR: 2.1; 95% CI: 1.09-3.92) and family history of asthma (OR: 1.9; 95% CI: 1.01-3.39). Birth from 36 weeks to 36 + 6 days mitigated RSVH risk (relative risk: 0.58; 95% CI: 0.34-0.99); however, risk factors were similar to the 32-35 weeks of GA cohort. CONCLUSION: Neonatal respiratory morbidity or being Caucasian were the population-specific independent risk factors for RSVH in 32-36 weeks of GA in Ireland, whereas the other identified independent risk factors mirrored those established in previous studies.
Authors: Maarten O Blanken; Bosco Paes; Evan J Anderson; Marcello Lanari; Margaret Sheridan-Pereira; Scot Buchan; John R Fullarton; ElizaBeth Grubb; Gerard Notario; Barry S Rodgers-Gray; Xavier Carbonell-Estrany Journal: Pediatr Pulmonol Date: 2018-02-06
Authors: Amanuel Tesfay Gebremedhin; Alexandra B Hogan; Christopher C Blyth; Kathryn Glass; Hannah C Moore Journal: Sci Rep Date: 2022-01-10 Impact factor: 4.379
Authors: Josep Figueras-Aloy; Paolo Manzoni; Bosco Paes; Eric A F Simões; Louis Bont; Paul A Checchia; Brigitte Fauroux; Xavier Carbonell-Estrany Journal: Infect Dis Ther Date: 2016-09-14